Company Overview
Unicycive Therapeutics, Inc. operates as a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies designed to address unmet medical needs within the United States. The company's primary asset is UNI 494, a pro-drug of Nicorandil that is currently being developed as a specific treatment for acute kidney injury. This entity functions within the broader Healthcare sector and the specialized Biotechnology industry, a space characterized by high research and development costs and long timelines to commercialization. As of the latest available data, the company holds a market capitalization of $142.92M and employs a workforce of 22 individuals. The current market cap of $142.92M indicates that Unicycive is a small-cap entity with limited annual revenue and a relatively modest operational scale compared to large-cap pharmaceutical peers.
Financial Health
Unicycive Therapeutics, Inc. reports a revenue (TTM) of N/A, a net income (TTM) of $-33,412,000, and an EBITDA of $-31,523,000, reflecting its status as a pre-revenue clinical-stage enterprise. The substantial gap between the reported revenue (TTM) of N/A and the significant net income loss of $-33,412,000 reveals a cost structure dominated by research and development expenditures rather than cost of goods sold or operational expenses. The company's free cash flow stands at $-16,055,250, which indicates that the organization is burning cash to fund its clinical trials and development pipeline without yet generating positive operating cash flow. Analysis of all three margins shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, levels that are typical for early-stage biotechnology firms that have not yet achieved commercial sales to generate gross profit. In terms of leverage, the company holds $42.70M in cash against $265,000 in debt, resulting in a debt-to-equity ratio of 0.71, which suggests a conservative balance sheet with minimal interest-bearing obligations relative to equity. The current ratio is listed at 3.83, a figure that indicates strong short-term liquidity and the ability to cover current liabilities with current assets well over three times their value. Furthermore, the return on equity is -102.3% and the return on assets is -44.2%, metrics that reveal that management has not yet generated positive returns on the capital invested, a common characteristic for companies in the clinical development phase before product launch.
Valuation Assessment
The valuation metrics for Unicycive Therapeutics, Inc. show a P/E Ratio (TTM) of N/A due to negative earnings, while the forward P/E is 1.14, a figure that implies the market is pricing in potential future earnings recovery or is utilizing alternative valuation models for this loss-making entity. The price-to-book ratio stands at 3.70, indicating that the market values the company at a premium of 3.7 times its net asset value, which often reflects the intangible value of its intellectual property and drug candidates despite current losses. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of -3.19, figures that suggest the market is not using traditional earnings-based multiples but is likely focusing on asset-backed or clinical milestone valuations. The stock has a 52-week high of $11.00 and a 52-week low of $3.71, and without a specific current price provided in the source data, the valuation context is defined strictly by this trading range where the security has demonstrated significant volatility. The beta value is 1.82, which signifies that the stock is expected to be substantially more volatile than the broader market, moving nearly twice as much in either direction relative to the S&P 500 during periods of market movement.
Growth & Income
The revenue growth (YoY) is N/A and the earnings growth (YoY) is N/A, as the company has not yet generated consistent commercial revenue to calculate year-over-year growth rates. Since there is no revenue or earnings growth data available, it is impossible to determine whether earnings are growing faster or slower than revenue, as both metrics are currently undefined for a pre-revenue entity. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings or capital are reinvested into growth initiatives rather than distributed to shareholders. The overall growth and income profile for Unicycive Therapeutics, Inc. is defined by a focus on clinical development and capital preservation rather than immediate income generation or historical revenue expansion.